Text size :

Asthma and polyposis, Palcic (Sifo Fvg): “Ultra long-acting treatments useful for patients and NHS”

ADNKRONOS

November 9, 2026

Rome, Nov 9. (Adnkronos Health) – In the management of severe asthma and chronic rhinosinusitis with nasal polyposis, “the challenge is to transform therapeutic progress into a path for citizens that truly creates value, both for the patient and for the public healthcare system. These pathologies present a significant burden related to type 2 inflammation, for which it is not enough to intervene episodically on the symptom: we must aim for continuous suppression of inflammation. The frequency of treatment is important, but it is equally important that inflammation control is maintained over time. Ultra long-acting compounds, which support inflammation suppression and involve semi-annual administration, certainly advantageous for patients too, are moving in this direction.” So said Stefano Palcic, director of the Territorial Pharmaceutical Governance SC of the Giuliano Isontina University Health Authority, Sifo advisor for the Friuli Venezia Giulia Region, participating in the national Congress of the Italian Society of Hospital Pharmacy and Pharmaceutical Services of Health Companies, which concluded yesterday in Rome.

“The value of a therapy does not only concern efficacy and frequency of administration, but also includes logistical aspects, staff employment, and the organization of care management,” explains Palcic, who is also an adjunct professor of Pharmacoeconomics at the University of Trieste. “The healthcare system must be able to measure, completely and without distortions, the entire patient care pathway,” he adds. “It should be remembered, in fact, that a patient not adequately treated can experience a worsening of the pathology, with even higher costs for the National Health Service, for example due to possible hospitalizations. What matters,” he emphasizes, “is to ensure that the healthcare system effectively treats people and makes the best use of available resources. For the patient, a lower frequency of administration can reduce access to healthcare facilities and travel, with positive repercussions also on the quality of life, a fundamental aspect.”

In this context, “the NHS pharmacist, operating in hospital pharmacies, but also in territorial pharmaceutical services,” clarifies Palcic, “contributes to measuring and making visible the value of the drug together with other professionals, working within a multi-stakeholder network. The pharmacist can bring to this network their own vision and culture of the drug, the concepts of efficacy, safety, and allocative efficiency, helping to better utilize available resources and, at the same time, to achieve health outcomes for citizens. The potential value of ultra-long acting therapies goes beyond efficacy, safety, and tolerability. It must also include organizational dimensions, those related to the healthcare system, and the sustainability of the entire care pathway.”

Jiji Press

Related

Page TOP